外泌体lncRNA在结直肠癌液体活检中的研究进展

doi:10.16352/j.issn.1001-6325.2023.02.317

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (2): 317-321.doi: 10.16352/j.issn.1001-6325.2023.02.317

外泌体lncRNA在结直肠癌液体活检中的研究进展

姚刘旭^1,2, 李玉红^3*, 蒋宗明^1*

1.绍兴市人民医院麻醉科,浙江绍兴 312000;
2.绍兴文理学院医学院,浙江绍兴 312000;
3.浙江树人大学树兰国际医学院附属树兰(杭州)医院麻醉科,浙江杭州 310004

收稿日期:2021-08-27 修回日期:2022-04-07 出版日期:2023-02-05 发布日期:2023-02-02
通讯作者: ^*yuh_li@zju.edu.cn; jiangzhejiang120@163. com
基金资助:
浙江省科学技术厅公益项目(Y21H150002,LGF19H030011);绍兴市人民医院青年科研基金项目(2020YB15);绍兴市公益项目(2020A13014);绍兴市麻醉学重点学科项目(2019SZD04)

Research progress of exosome lncRNA in liquid biopsy of colorectal cancer

YAO Liuxu^1,2, LI Yuhong^3*, JIANG Zongming^1*

1. Department of Anesthesiology, Shaoxing People’s Hospital, Shaoxing 312000;
2. School of Medicine, Shaoxing University Shaoxing 312000;
3. Department of Anesthesiology, Shulan Hospital (Hangzhou), Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310004, China

Received:2021-08-27 Revised:2022-04-07 Online:2023-02-05 Published:2023-02-02
Contact: ^*yuh_li@zju.edu.cn; jiangzhejiang120@163. com

摘要/Abstract

摘要： 目前针对结直肠癌(CRC) 的诊断技术仍在不断完善。液体活检主要对生物源液体特定成分进行分析,外泌体来源的长链非编码RNA (lncRNA)可以通过液体活检技术分析。

关键词: 结直肠癌, 液体活检, 外泌体, lncRNA, 生物标志物

Abstract: The diagnostic methods for colorectal cancer (CRC) are still improving. Liquid biopsy mainly analyzes the specific components of biological liquid. Long chain noncoding RNA (lncRNA) from exosomes can be analyzed by liquid biopsy technology.

Key words: colorectal cancer, liquid biopsy, exosome, lncRNA, biomarkers

中图分类号:

R735.3

姚刘旭, 李玉红, 蒋宗明. 外泌体lncRNA在结直肠癌液体活检中的研究进展[J]. 基础医学与临床, 2023, 43(2): 317-321.

YAO Liuxu, LI Yuhong, JIANG Zongming. Research progress of exosome lncRNA in liquid biopsy of colorectal cancer[J]. Basic & Clinical Medicine, 2023, 43(2): 317-321.

参考文献 25

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68:394-424.
[2]	Rapado-González ó, álvarez-Castro A, López-López R, et al. Circulating microRNAs as promising biomarkers in colorectal cancer[J]. Cancers, 2019, 11:898.doi:10.3390/cancers11070898.
[3]	Wang S, Zhang K, Tan S, et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies[J]. Mol Cancer, 2021, 20:13.doi:10.1186/s12943-020-01298-z.
[4]	Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18:297-312.
[5]	Dai J, Su Y, Zhong S, et al. Exosomes: key players in cancer and potential therapeutic strategy[J]. Signal Transduct Target Ther, 2020, 5:145.doi:10.1038/s41392-020-00261-0.
[6]	Rinn JL, Chang HY. Long Noncoding RNAs: molecular modalities to organismal functions[J]. Annu Rev Biochem, 2020, 89:283-308.
[7]	Mehryab F, Rabbani S, Shahhosseini S, et al. Exosomes as a next-generation drug delivery system: an update on drug loading approaches, characterization, and clinical application challenges[J]. Acta Biomater, 2020, 113:42-62.
[8]	Yue B, Yang H, Wang J, et al. Exosome biogenesis, secretion and function of exosomal miRNAs in skeletal muscle myogenesis[J]. Cell Prolif, 2020, 53:e12857.doi:10.1111/cpr.12857.
[9]	Goodall GJ, Wickramasinghe VO. RNA in cancer[J]. Nat Rev Cancer, 2021, 21:22-36.
[10]	Yao R, Wang Y, Chen L. Cellular functions of long noncoding RNAs[J]. Nature Cell Biology, 2019, 21:542-551.
[11]	Liu ZW, Zhao N, Su YN, et al. Exogenously overex-pressed intronic long noncoding RNAs activate host gene expression by affecting histone modification in arabidopsis[J]. Sci Rep, 2020, 10:3094.doi:10.1038/s41598-020-59697-7.
[12]	Lu C, Wei Y, Wang X, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma[J]. Mol Cancer, 2020, 19:28.doi:10.1186/s12943-020-1137-5.
[13]	Han M, Wang S, Fritah S, et al. Interfering with long non-coding RNA MIR22HG processing inhibits glioblas-toma progression through suppression of Wnt/β-catenin signalling[J]. Brain, 2020, 143:512-530.
[14]	Liang ZX, Liu HS, Wang FW, et al. LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization[J]. Cell Death Dis, 2019, 10:829.doi:10.1138/s41419-019-2077-0.
[15]	Cai H, Yu Y, Ni X, et al. LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis[J]. Cell Death Dis, 2020, 11:1032.doi:10.1038/s41419-020-03247-6.
[16]	Luan Y, Li X, Luan Y, et al. Circulating lncRNA UCA1 promotes malignancy of colorectal cancer via the miR-143/MYO6 axis[J]. Mol Ther Nucleic Acids, 2020, 19:790-803.
[17]	Barbagallo C, Brex D, Caponnetto A, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions[J]. Mol Ther Nucleic Acids, 2018, 12:229-241.
[18]	Yang YN, Zhang R, Du JW, et al. Predictive role of UCA1-containing exosomes in cetuximab-resistant color-ectal cancer[J]. Cancer Cell Int, 2018, 18:164.doi:10.1186/s12935-018-0660-6.
[19]	Yu B, Du Q, Li H, et al. Diagnostic potential of serum exosomal colorectal neoplasia differentially expressed long non-coding RNA (CRNDE-p) and microRNA-217 expression in colorectal carcinoma[J]. Oncotarget, 2017, 8:83745-83753.
[20]	Sun J, Jia H, Bao X, et al. Tumor exosome promotes Th17 cell differentiation by transmitting the lncRNA CRNDE-h in colorectal cancer[J]. Cell Death Dis, 2021, 12:123.doi:10.1038/s41419-020-03376-y.
[21]	Ren J, Ding L, Zhang D, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19[J]. Theranostics, 2018, 8:3932-3948.
[22]	Oehme F, Krahl S, Gyorffy B, et al. Low level of exosomal long non-coding RNA HOTTIP is a prognostic biomarker in colorectal cancer[J]. RNA Biol, 2019, 16:1339-1345.
[23]	Zhao Y, Du T, Du L, et al. Long noncoding RNA LINC02418 regulates MELK expression by acting as a ceRNA and may serve as a diagnostic marker for colorectal cancer[J]. Cell Death Dis, 2019, 10:568.doi:10.1038/s41419-019-1804-x.
[24]	Wang L, Duan W, Yan S, et al. Circulating long non-coding RNA colon cancer-associated transcript 2 protected by exosome as a potential biomarker for colorectal cancer[J]. Biomed Pharmacother, 2019, 113:108758.doi:1016/j.biopha.2019.108758.
[25]	Choi JU, Park IK, Lee YK, et al. The biological function and therapeutic potential of exosomes in cancer: exosomes as efficient nanocommunicators for cancer therapy[J]. Int J Mol Sci, 2020, 21:7363.doi:10.3390/ijms21197363.

外泌体lncRNA在结直肠癌液体活检中的研究进展

Research progress of exosome lncRNA in liquid biopsy of colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于曼殊, 赵晓敏, 邱明月, 刘春冉, 那日苏. 牙源性干细胞治疗帕金森病的研究进展[J]. 基础医学与临床, 2024, 44(9): 1298-1302.
[2]	周昌东, 林洋, 孙凯, 田玉新. 敲降lncRNA UCA1降低人膀胱癌细胞系T24对吉西他滨耐药[J]. 基础医学与临床, 2024, 44(8): 1113-1119.
[3]	赵俊丽, 朱君君, 詹秋楠, 刘苗. 骨髓间充质干细胞来源外泌体抑制高糖诱导的腹膜间皮细胞EMT[J]. 基础医学与临床, 2024, 44(8): 1149-1156.
[4]	高璐, 蔡孟华, 许依, 何维, 陈慧, 张建民. 过表达膜定位IL-3的293T细胞外泌体的纯化及体外功能验证[J]. 基础医学与临床, 2024, 44(7): 947-953.
[5]	李运龙, 李蕊, 张玉萍, 王瑞, 刘燕萍. 孕期锌缺乏及对妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 422-427.
[6]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[7]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.
[8]	方路, 刘睿奇, 梁鹏, 岑瑛. 外泌体miRNAs在器官纤维化中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1472-1476.
[9]	杨雅倩, 潘艳芳, 屈梦扬, 方艳, 应小平, 张玫倩, 魏静. 外泌体在肝癌前病变发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1453-1456.
[10]	张亮亮, 赵程锦, 周煜虎, 曹博, 段明明, 冯阳阳. LncRNA FGD5-AS1调节miR-93-5p/BMP2轴促进人骨髓间充质干细胞成骨分化[J]. 基础医学与临床, 2023, 43(8): 1179-1185.
[11]	陈星星, 赛依帕, 胡筱霞, 王三萍, 罗璇, 刘璟. 人脐带间充质干细胞来源外泌体对脑瘫小鼠神经功能损伤的保护作用[J]. 基础医学与临床, 2023, 43(8): 1201-1207.
[12]	杜风, 陈翌阳, 张楠, 徐俊玄, 宁婷婷, 朱圣韬, 张澍田. FOXL2NB在结直肠癌中的表达和临床意义[J]. 基础医学与临床, 2023, 43(6): 909-915.
[13]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[14]	闫霖, 陆珏秀, 罗颖, 刘先霞. BM-MSCs来源外泌体介导铁死亡减轻大鼠心肌细胞系H9c2缺氧/复氧损伤[J]. 基础医学与临床, 2023, 43(5): 771-776.
[15]	张燕萍, 姚刘旭, 丁倩男, 黄则勇, 李玉红, 黄素琴. 结直肠癌PDX模型成瘤率的影响因素及临床意义[J]. 基础医学与临床, 2023, 43(4): 596-602.